Roadshow
ENERGI-Platform
Energenesis Biomedical (Taiwan Listed Company) is a leading biotech company focused on developing innovative drugs.
We utilize the ENERGI platform to develop viable therapeutics that promote self-healing in the human body. Our ongoing projects focus on new drugs for chronic wound care, alopecia, neurodegenerative diseases, and other unmet needs.
ENERGI-F705PD: An oral small-molecule drug for Parkinson’s disease, targeting alpha-synuclein aggregation as a novel disease-modifying approach. The program has entered Phase I clinical trials, with plans to progress to Phase II following successful results.
ENERGI-F703DFU: A topical gel for diabetic foot ulcers, currently in Phase III clinical development.
ENERGI-F701: A topical solution for hair loss prevention, which has successfully completed Phase II clinical trials.
ENERGI-F703EB: A topical cream for epidermolysis bullosa (EB), a rare genetic skin disorder. The program has received Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) designation from the U.S. FDA, as well as Orphan Medicinal Product Designation from the European Medicines Agency (EMA). The program is advancing toward Phase II clinical trials.
In addition, Energenesis is strategically integrating AI-powered drug repurposing to identify new indications for existing drugs, accelerating the development of innovative therapies.
Join us at BIO 2025, June 16-19 in Boston, where Energenesis Biomedical Co., Ltd. will be showcasing our cutting-edge solutions and services. We can't wait to connect with you to discuss how we're shaping the future of biotechnology. Find us at Booth 1645. See you there!
#BIO2025#TAIWAN PAVILION
Energenesis Biomedical leverage the ENERGI platform, centered on the small molecule ENERGI, to activate key enzymes that boost cellular ATP production.
ATP plays a critical role in cellular health, and its decline is closely linked to aging and neurodegenerative diseases. By restoring energy balance, the ENERGI platform offers a novel therapeutic approach across multiple disease areas.
- Established 2012
- Company Energenesis Biomedical Co., Ltd.
- Telephone +886-2-2627-0835
- Email shelly@energenesis-biomedical.com
- Address 6F.-3, No.21, Ln.583, Ruiguang Rd., Neihu Dist., Taipei 11492, Taiwan
Energenesis Biomedical (Taiwan Listed Company) is a leading biotech company focused on developing innovative drugs.
We utilize the ENERGI platform to develop viable therapeutics that promote self-healing in the human body. Our ongoing projects focus on new drugs for chronic wound care, alopecia, neurodegenerative diseases, and other unmet needs.
ENERGI-F705PD: An oral small-molecule drug for Parkinson’s disease, targeting alpha-synuclein aggregation as a novel disease-modifying approach. The program has entered Phase I clinical trials, with plans to progress to Phase II following successful results.
ENERGI-F703DFU: A topical gel for diabetic foot ulcers, currently in Phase III clinical development.
ENERGI-F701: A topical solution for hair loss prevention, which has successfully completed Phase II clinical trials.
ENERGI-F703EB: A topical cream for epidermolysis bullosa (EB), a rare genetic skin disorder. The program has received Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) designation from the U.S. FDA, as well as Orphan Medicinal Product Designation from the European Medicines Agency (EMA). The program is advancing toward Phase II clinical trials.
In addition, Energenesis is strategically integrating AI-powered drug repurposing to identify new indications for existing drugs, accelerating the development of innovative therapies.